Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19252441 | ANTI-TREM2 AGONIST ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF THAT CAN INCREASE LEVELS OF SOLUBLE TREM2 IN SERUM AND BRAIN TISSUE | June 2025 | November 2025 | Allow | 5 | 1 | 1 | Yes | No |
| 18966342 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) | December 2024 | January 2026 | Abandon | 14 | 1 | 0 | No | No |
| 18759577 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | June 2024 | October 2025 | Abandon | 16 | 1 | 1 | No | No |
| 18592478 | RETINAL PIGMENT EPITHELIAL CELL TRANSPLANTATION FOR THE TREATMENT OF CORNEAL ENDOTHELIAL DYSFUNCTION | February 2024 | January 2025 | Abandon | 11 | 1 | 1 | Yes | No |
| 18368431 | METHODS FOR REDUCING SYMPTOMS OF MULTIPLE SCLEROSIS USING A SIX-AMINO ACID LONG PEPTIDE THAT INHIBITS CD40-CD154 INTERACTION | September 2023 | July 2025 | Allow | 22 | 1 | 1 | Yes | No |
| 18360073 | TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF Fab | July 2023 | April 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18352690 | Application of Retinal Pigment Epithelial Cells as Corneal Endothelial Substitute | July 2023 | January 2025 | Abandon | 19 | 2 | 1 | Yes | No |
| 18217160 | TREATING OPTIC NEURITIS WITH INDUCED PLURIPOTENT STEM CELL-DERIVED OLIGODENDROCYTE PRECURSOR CELLS | June 2023 | November 2025 | Abandon | 29 | 1 | 1 | No | No |
| 18340786 | PH20 POLYPEPTIDE VARIANTS WITH A MODIFICATION AT POSITION 324 OF THE PH20 POLYPEPTIDE AND A METHOD OF MAKING THEREOF | June 2023 | August 2024 | Allow | 14 | 2 | 1 | Yes | No |
| 18325690 | DIFFERENTIATION OF CORTICAL NEURONS FROM HUMAN PLURIPOTENT STEM CELLS | May 2023 | February 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18143917 | MATERIALS AND METHODS FOR EVALUATING AND TREATING NEUROMYELITIS OPTICA (NMO) | May 2023 | February 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18304018 | WNT SIGNALING AGONIST MOLECULES | April 2023 | August 2025 | Abandon | 28 | 1 | 0 | No | No |
| 18019275 | METHODS OF TFEB ACTIVATION AND LYSOSOMAL BIOGENESIS AND COMPOSITIONS THEREFOR | February 2023 | May 2025 | Abandon | 27 | 1 | 1 | No | No |
| 18160156 | USE OF N-BUTYLIDENEPHTHALIDE IN DOPAMINERGIC PROGENITOR CELL TRANSPLANTATION | January 2023 | October 2025 | Abandon | 33 | 2 | 0 | No | No |
| 18159483 | METHODS OF TREATING SPINAL CORD INJURY USING A SUPRESSOR OF CYTOKINE SIGNALING-3 (SOCS3) REDUCTION PEPTIDE (SRP) COMPRISING A CELL MEMBRANE PENETRATING DOMAIN, A SOCS3 BINDING DOMAIN, AND A LYSOSOME TARGETING DOMAIN | January 2023 | March 2025 | Allow | 25 | 1 | 1 | Yes | No |
| 18004772 | ANTI-TAU ANTIBODIES AND METHODS OF USE THEREOF | January 2023 | January 2026 | Allow | 36 | 1 | 0 | Yes | No |
| 18150740 | ADENO-ASSOCIATED VIRUS FOR THERAPEUTIC DELIVERY TO CENTRAL NERVOUS SYSTEM | January 2023 | August 2025 | Abandon | 32 | 1 | 1 | No | No |
| 18085418 | A BINDING MOLECULE BINDING TO TRAUMATIC BRAIN INJURY-ASSOCIATED TAU AND METHODS OF USE THEREOF | December 2022 | February 2026 | Allow | 38 | 1 | 1 | Yes | No |
| 18073951 | METHODS OF REDUCING SEVERITY OF GLAUCOMA BY INTRAVITREAL ADMINISTRATION OF INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-LIKE 1 (IGFBPL1) | December 2022 | January 2025 | Allow | 26 | 2 | 0 | No | No |
| 17999822 | MONOCLONAL ANTIBODIES AGAINST PATHOLOGICAL TAU, AND METHODS OF DETECTION THEREOF | November 2022 | February 2026 | Allow | 39 | 1 | 1 | Yes | No |
| 18057273 | MIMOTOPES OF ALPHA-SYNUCLEIN AND VACCINES THEREOF FOR THE TREATMENT OF SYNUCLEINOPATHY | November 2022 | February 2026 | Allow | 39 | 2 | 1 | No | No |
| 17932264 | WNT SIGNALING AGONIST MOLECULES | September 2022 | January 2025 | Abandon | 28 | 0 | 2 | No | No |
| 17944699 | PAR2 MODULATION TO ALTER MYELINATION | September 2022 | March 2025 | Abandon | 31 | 1 | 1 | No | No |
| 17941117 | DETERMINING ONSET OF AMYOTROPHIC LATERAL SCLEROSIS | September 2022 | March 2025 | Abandon | 31 | 1 | 1 | No | No |
| 17893132 | SYSTEM AND METHOD FOR GENE EDITING BY USING ENGINEERED CELL | August 2022 | June 2025 | Abandon | 34 | 2 | 1 | No | No |
| 17887377 | COMPLEMENT FACTOR Bb ANTIBODIES | August 2022 | November 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17866900 | NEURONAL VIABILITY FACTOR AND USE THEREOF | July 2022 | February 2025 | Abandon | 31 | 1 | 1 | No | No |
| 17811174 | ERYTHROPOIETIN-DERIVED PEPTIDES and METHODS OF PROTECTING CELLS FROM OXIDATIVE DAMAGE INDUCED BY REACTIVE OXYGEN SPECIES | July 2022 | December 2024 | Allow | 30 | 1 | 1 | Yes | No |
| 17810113 | HUMAN-DERIVED ANTI-HUNTINGTIN (HTT) ANTIBODIES AND USES THEREOF | June 2022 | January 2026 | Abandon | 43 | 2 | 1 | No | No |
| 17789946 | ANTIBODY BINDING TO SUPER-REPRESSOR IkB (srIkB) OR ANTIGEN BINDING FRAGMENT THEREOF | June 2022 | August 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17846302 | ANTI-TAU ANTIBODIES AND METHODS OF USE | June 2022 | November 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17737439 | TREM2 ANTIBODIES AND USES THEREOF | May 2022 | January 2026 | Allow | 44 | 1 | 1 | Yes | No |
| 17771680 | METHODS FOR DIAGNOSIS AND TREATMENT | April 2022 | October 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17770772 | ANTI-NOGO-A ANTIBODIES and METHODS OF MAKING and USING THEREOF | April 2022 | February 2026 | Allow | 46 | 1 | 1 | Yes | No |
| 17723674 | ANTI-PACAP ANTIBODIES, NUCLEIC ACIDS AND METHODS OF MAKING THEREOF | April 2022 | October 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17721715 | METHODS OF REDUCING FUS/TLS- OR TDP-43-MEDIATED NEURONAL CYTOTOXICITY IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) BY UPF2 | April 2022 | December 2024 | Allow | 32 | 1 | 0 | Yes | No |
| 17719627 | BRAIN-CHIP MODELING NEURODEGENERATION AND NEUROINFLAMMATION IN PARKINSON'S DISEASE | April 2022 | November 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17766307 | AUTONOMOUS INDUCIBLE DIRECTED EVOLUTION OF COMPLEX PATHWAYS | April 2022 | October 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17683948 | SGEF CONTROLS MACULAR, CORPUS CALLOSUM AND HIPPOCAMPAL FUNCTION AND DEVELOPMENT, LIVER HOMEOSTASIS, FUNCTIONS OF THE IMMUNE SYSTEM, FEVER RESPONSE ATHEROSCLEROSIS AND TUMOROGENIC CELL GROWTH | March 2022 | November 2024 | Abandon | 33 | 0 | 1 | No | No |
| 17681011 | METHODS FOR TREATING ALZHEIMER'S DISEASE | February 2022 | December 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17577816 | THERMORESPONSIVE HYDROGEL CONTAINING POLYMER MICROPARTICLES FOR NONINVASIVE OCULAR BIOLOGIC DELIVERY | January 2022 | February 2026 | Abandon | 49 | 4 | 1 | No | No |
| 17617908 | Improved Retinal Organoids And Methods Of Making The Same | December 2021 | May 2025 | Abandon | 42 | 4 | 1 | No | No |
| 17457727 | TREATMENT OF DISEASES RELATED TO ATP-BINDING CASSETTE TRANSPORTER 1 DYSFUNCTION USING TREM2 AGONISTS | December 2021 | December 2024 | Abandon | 37 | 2 | 1 | No | No |
| 17614008 | ANTI-APOE ANTIBODIES AND POLYNUCLEOTIDES THEREOF | November 2021 | February 2025 | Allow | 38 | 1 | 1 | Yes | No |
| 17506406 | METHODS FOR DETECTING A GENETIC VARIATION IN ATTRACTIN-LIKE 1 (ATRNL1) GENE IN SUBJECT WITH PARKINSON'S DISEASE | October 2021 | May 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17495458 | A METHOD FOR SUPPRESSING OR ALLEVIATING PRIMARY OR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS OR SPMS) USING A SUSTAINED RELEASE DEPOT FORMULATION COMPRISING GLATIRAMER ACETATE | October 2021 | February 2025 | Allow | 41 | 4 | 0 | Yes | No |
| 17490505 | Methods of Use of Soluble CD24 for Neuroprotection and Remyelination | September 2021 | November 2024 | Abandon | 38 | 3 | 0 | Yes | No |
| 17440733 | COMPOSITION FOR PREVENTING OR TREATING BRAIN AND NERVOUS SYSTEM DISEASE | September 2021 | April 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17401879 | METHOD OF TREATMENT TO PREVENT OR REVERSE AGE-ASSOCIATED INFLAMMATION, COGNITIVE DECLINE, AND NEURODEGENERATION | August 2021 | November 2024 | Abandon | 39 | 2 | 1 | Yes | Yes |
| 17428588 | THERAPEUTIC TARGET AND MONOCLONAL ANTIBODIES AGAINST IT FOR THE DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE | August 2021 | November 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17259425 | ANTI-ABETA ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF | August 2021 | February 2025 | Allow | 49 | 1 | 1 | Yes | No |
| 17427589 | HUMANIZED ANTI-A[BETA] MONOCLONAL ANTIBODY AND APPLICATION THEREOF | July 2021 | December 2024 | Allow | 40 | 2 | 1 | Yes | No |
| 17427584 | HUMANIZED ANTI-A[BETA] MONOCLONAL ANTIBODY AND APPLICATION THEREOF | July 2021 | October 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17346974 | BINDING AGONIST FOR TREATMENT OF NEUROLOGICAL AND OTHER DISORDERS | June 2021 | October 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17312854 | ANTIBODIES BINDING TO PHOSPHO-TAU COMPRISING PHOSPHORYLATED Ser396 AND Ser404 AND METHODS OF DETECTING THEREOF | June 2021 | March 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17281509 | METHODS FOR DIAGNOSING OR TREATING POST-TRAUMATIC STRESS DISORDER, AND COMPOSITIONS THEREFOR | March 2021 | June 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17201424 | METHODS OF DETERMINING WHETHER ANTI-PACAP ANTIBODIES INHIBIT PACAP-ASSOCIATED PHOTOPHOBIA OR LIGHT AVERSION | March 2021 | November 2025 | Abandon | 56 | 3 | 1 | No | No |
| 17179846 | METHODS OF REDUCING COGNITIVE IMPAIRMENT AND LEARNING AND MEMORY DEFICITS CAUSED BY A P301L MUTATION IN MICROTUBULE-ASSOCIATED PROTEIN TAU (MAPT) PROTEIN IN PATIENTS WITH ALZHEIMER’S DISEASE USING AN AAV9 VECTOR ENCODING A PHOSPHOMIMETIC (S/D) HSP22 MUTANT | February 2021 | August 2025 | Allow | 54 | 5 | 0 | Yes | No |
| 17113778 | METHODS FOR ALLEVIATING FACIOSCAPULOHUMERAL DYSTROPHY (FSHD) BY AN ANTISENSE NUCLEIC ACID MOLECULE INHIBITING THE EXPRESSION OF Double homeobox 4 (DUX4) | December 2020 | January 2026 | Allow | 60 | 4 | 0 | Yes | Yes |
| 15734125 | PEPTIDES FOR INHIBITING CHOLINERGIC CALCITONIN GENE-RELATED PEPTIDE (CGRP) AND ACETYLCHOLINE (ACH) RELEASE or INHIBITING SENSITIZATION-MEDIATED BY TRPV1-MEDIATED EXCITABILITY IN SENSORY NEURONS AND METHODS OF USE THEREOF | December 2020 | April 2025 | Allow | 52 | 2 | 1 | Yes | No |
| 16976841 | METHODS AND COMPOSITIONS FOR MRNA-BASED MODULATION AND DETECTION OF CELL PHENOTYPES | August 2020 | May 2025 | Abandon | 57 | 2 | 1 | No | No |
| 16989450 | BLOOD-BRAIN BARRIER PERMEABLE PEPTIDE COMPOSITIONS | August 2020 | November 2024 | Abandon | 51 | 5 | 1 | Yes | No |
| 16962590 | A MEDIUM COMPRISING SERUM REPLACEMENT, IGF1, STAT3 ACTIVATOR AND ADRENAL GLAND HORMONE WITHOUT BFGF OR ROCK INHIBITOR FOR PRODUCING CORNEAL ENDOTHELIAL SUBSTITUTE CELLS FROM IPS CELLS AND A METHOD THEREOF | July 2020 | April 2025 | Allow | 57 | 4 | 1 | Yes | No |
| 16924902 | THERAPEUTIC AGENTS FOR OCULAR INFLAMMATORY DISEASE COMPRISING INTERLEUKIN 6 RECEPTOR INHIBITOR AS ACTIVE INGREDIENT | July 2020 | August 2025 | Abandon | 60 | 6 | 0 | No | No |
| 16869224 | DERIVATION OF SOMATOTROPHS FROM STEM CELLS AND USES THEREOF | May 2020 | January 2025 | Abandon | 56 | 2 | 1 | No | Yes |
| 16757254 | DOMINANT NEGATIVE SARM1 MOLECULES COMPRISING A SUBSTITUTION AT POSITION 189, 190, 193, 194, 570 AND/OR 685 of SARM1 | April 2020 | November 2025 | Allow | 60 | 3 | 1 | Yes | No |
| 16755089 | METHODS AND DEVICES FOR PROMOTING NERVE GROWTH AND REGENERATION | April 2020 | October 2025 | Abandon | 60 | 4 | 1 | Yes | Yes |
| 16643668 | Combination Therapy of Lasmiditan and a CGRP Antagonist for Use in the Treatment of Migraine | March 2020 | August 2025 | Abandon | 60 | 6 | 0 | No | No |
| 16642307 | A METHOD OF PROLONGING THE LIFESPAN OF PATIENTS WITH CEREBRAL AUTOSOMAL DOMINANT ARTERIOPATHY WITH SUBCORTICAL INFARCTS AND LEUKOENCEPHALOPATHY (CADASIL) USING A CEREBROLYSIN® PREPARATION | February 2020 | December 2025 | Allow | 60 | 6 | 0 | Yes | No |
| 16639185 | METHODS FOR TREATING HUNTINGTON’S DISEASE USING A POLYNUCLEOTIDE ENCODING A VTFT ISOFORM OF A BPIFB4 PROTEIN | February 2020 | January 2025 | Allow | 59 | 3 | 1 | Yes | No |
| 16631676 | HUMANIZED ANTIBODIES BINDING TO AMYLOID-BETA (A-BETA) | January 2020 | December 2024 | Allow | 59 | 7 | 1 | Yes | No |
| 16732109 | METHOD FOR IDENTIFYING EFFECTIVE TREATMENTS AGAINST NEURODEGENERATIVE DISORDERS | December 2019 | January 2025 | Abandon | 60 | 2 | 1 | No | Yes |
| 16625222 | METHODS OF PREVENTING AND TREATING DISEASES CHARACTERIZED BY SYNAPTIC DYSFUNCTION AND NEURODEGENERATION INCLUDING ALZHEIMER'S DISEASE | December 2019 | June 2025 | Abandon | 60 | 6 | 0 | Yes | No |
| 16607229 | Method For Separation Of Dopaminergic Neural Cells And Pharmaceutical Composition Comprising Dopaminergic Neural Cells For Treatment Of Parkinson's Disease | October 2019 | June 2025 | Abandon | 60 | 5 | 1 | No | No |
| 16488380 | A METHOD OF IDENTIFYING L/M-OPSIN AND CRX POSITIVE CONE PHOTORECEPTOR CELLS BASED ON SPECIFIC BIOMARKERS | August 2019 | December 2024 | Allow | 60 | 3 | 1 | Yes | No |
| 16543077 | COMPOSITION FOR TREATING STROKE AND METHOD FOR SCREENING THE SAME | August 2019 | November 2025 | Abandon | 60 | 8 | 1 | No | No |
| 16474587 | THERAPEUTIC METHOD USING TOLEROGENIC PEPTIDES | June 2019 | November 2025 | Abandon | 60 | 9 | 0 | Yes | No |
| 16442437 | METHODS AND COMPOSITIONS FOR REJUVENATING NEUROMUSCULAR JUNCTIONS | June 2019 | December 2024 | Abandon | 60 | 6 | 0 | No | Yes |
| 16463424 | HUMAN CELL POPULATION COMPRISING HUMAN RETINAL PROGENITOR CELLS WITHOUT AN ISL1 GENE FOR TRANSPLANTATION AND METHODS OF USE THEREOF | May 2019 | December 2024 | Allow | 60 | 5 | 1 | Yes | No |
| 16348089 | REDUCING ABNORMAL ACCUMULATION OF TDP-43 IN MOTOR NEURONS IN AMYOTROPHIC LATERAL SCLEROSIS AND/OR FRONTOTEMPORAL DEMENTIA USING A CONSTRUCT ENCODING CYCLIN F | May 2019 | July 2024 | Allow | 60 | 3 | 1 | Yes | No |
| 16099134 | AN IN VITRO METHOD OF REPROGRAMMING FIBROBLAST CELLS INTO INDUCED PLURIPOTENT STEM CELLS BY TRANSCRIPTION FACTORS MRNAS CO-TRANSFECTED WITH SOCS1 MRNA WHEREIN THE MRNAS HAVE A POLY-A TAIL OF AT LEAST 2000 ADENINES | November 2018 | December 2024 | Allow | 60 | 5 | 1 | Yes | No |
| 16138177 | Separation of Triple-Light Chain Antibodies Using Cation Exchange Chromatography | September 2018 | March 2025 | Abandon | 60 | 5 | 1 | Yes | No |
| 16083935 | Protein Stability-based Small Molecule Biosensors and Methods | September 2018 | March 2025 | Abandon | 60 | 5 | 1 | No | No |
| 16116271 | METHODS FOR CARDIOMYOCYTE SURVIVAL,PROLIFERATION OR DIFFERENTIATION BY NRG-2 | August 2018 | January 2020 | Allow | 17 | 1 | 1 | Yes | No |
| 16111500 | METHODS OF TREATING EPILEPSY, SEIZURE DISORDERS AND SUDDEN UNEXPECTED DEATH IN EPILEPSY | August 2018 | August 2025 | Abandon | 60 | 8 | 0 | Yes | No |
| 15577035 | METHOD FOR THE TREATMENT OF NEUROLOGICAL DISEASE | November 2017 | January 2019 | Allow | 14 | 1 | 1 | No | No |
| 15720907 | METHODS FOR TREATING BACK OR NECK PAIN CAUSED BY NGF USING A THERAPEUTIC AGENT COMPRISING REN-1820, ALE-0540 AND CAPSAICIN | September 2017 | August 2019 | Allow | 23 | 2 | 1 | Yes | No |
| 15555959 | Pain Treatment | September 2017 | October 2025 | Abandon | 60 | 7 | 2 | Yes | Yes |
| 15534934 | A COMPOSITION COMPRISING THREE-DIMENSIONAL ASTROCYTE BUNDLES OF BI-POLAR AND ALIGNED ASTROCYTE PROCESSES AND A METHOD OF MAKING THEREOF | June 2017 | December 2025 | Allow | 60 | 6 | 1 | Yes | Yes |
| 15399211 | METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS BY HGF | January 2017 | April 2018 | Allow | 16 | 1 | 0 | Yes | No |
| 15146780 | METHODS FOR MEASURING CONCENTRATIONS OF BIOMOLECULES | May 2016 | January 2026 | Abandon | 60 | 13 | 1 | No | No |
| 15142075 | N-11 TRUNCATED AMYLOID-BETA MONOCLONAL ANTIBODIES, COMPOSITIONS, METHODS AND USES | April 2016 | November 2017 | Allow | 19 | 1 | 1 | Yes | No |
| 15032677 | NEURONAL REPLACEMENT AND REESTABLISHMENT OF AXONAL CONNECTIONS | April 2016 | November 2024 | Abandon | 60 | 9 | 1 | No | Yes |
| 14897605 | METHOD FOR TREATING NEURODEGENERATIVE DISORDERS | December 2015 | January 2026 | Abandon | 60 | 8 | 1 | Yes | Yes |
| 14763023 | METHODS FOR SCREENING ANTI-PROTEIN AGGREGATION AGENTS USING SINGLE-STRANDED SPECIFIC RNASES TO INITIATE PROTEIN AGGREGATION | July 2015 | August 2017 | Allow | 25 | 2 | 1 | No | No |
| 14615083 | METHOD OF PROMOTING EXCITATORY SYNAPSE FORMATION WITH AN ANTI-EPHEXIN5 PHOSPHO-Y361 ANTIBODY | February 2015 | August 2016 | Allow | 19 | 1 | 1 | Yes | No |
| 14576706 | METHODS FOR PROTECTING DOPAMINERGIC NEURONS FROM STRESS AND PROMOTING PROLIFERATION AND DIFFERENTIATION OF OLIGODENDROCYTE PROGENITORS BY NRG-2 | December 2014 | April 2018 | Allow | 40 | 4 | 0 | Yes | No |
| 14482703 | CONJUGATES OF INSULIN-LIKE GROWTH FACTOR-1 AND POLY(ETHYLENE GLYCOL) | September 2014 | April 2017 | Allow | 31 | 2 | 1 | Yes | No |
| 14009360 | METHODS OF SCREENING COMPOUNDS FOR THE FIBRIL FORMATION OF ABETA PEPTIDES BASED ON A DECREASED TRIMER/MONOMER RATIO OF A CHAPERONE PROTEIN | October 2013 | August 2016 | Allow | 34 | 3 | 1 | Yes | No |
| 13778359 | METHOD FOR TREATING NEUROPATHIC PAIN | February 2013 | January 2014 | Allow | 11 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WANG, CHANG YU.
With a 61.5% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 38.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner WANG, CHANG YU works in Art Unit 1675 and has examined 128 patent applications in our dataset. With an allowance rate of 74.2%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 50 months.
Examiner WANG, CHANG YU's allowance rate of 74.2% places them in the 39% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by WANG, CHANG YU receive 3.36 office actions before reaching final disposition. This places the examiner in the 92% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by WANG, CHANG YU is 50 months. This places the examiner in the 5% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +26.6% benefit to allowance rate for applications examined by WANG, CHANG YU. This interview benefit is in the 74% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 13.1% of applications are subsequently allowed. This success rate is in the 8% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 41.5% of cases where such amendments are filed. This entry rate is in the 63% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 142.9% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 88% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 64.9% of appeals filed. This is in the 45% percentile among all examiners. Of these withdrawals, 54.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 65.5% are granted (fully or in part). This grant rate is in the 70% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 12.5% of allowed cases (in the 95% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.1% of allowed cases (in the 69% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.